Enterprise Therapeutics doses first person with cystic fibrosis in Phase 2 trial for novel therapy ETD001

FHS
July 24, 2024
10:28 am

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of those suffering from respiratory disease, today announced dosing of the first person with cystic fibrosis (pwCF) in its Phase 2a trial of ETD001.

Current Approaches to Smoldering Multiple Myeloma

Precancerous, or smoldering, multiple myeloma (SMM) is by definition an asymptomatic disease, and about 50% of those diagnosed with this precursor condition will develop full

July 13, 2024

Cannabis Use Tied to Increased Risk of Severe COVID

Cannabis use was significantly associated with a greater risk of severe outcomes following a COVID-19 infection, according to a retrospective study that spanned the first

June 22, 2024

RLDatix partners with RLDatix to Reduce Care Variability

What You Should Know: – RLDatix, the leading global provider of connected healthcare operations software and services, announced the expansion of its partnership with USA Health,

October 8, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.